Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

Last Updated on November 16, 2022 by GlobeNewsWire

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 12:35pm ET. The Conference will be held virtually from November 29th – December 1st, during which Agenus will host one-on-one meetings with investors.

Registration for the webcast can be accessed at https://wsw.com/webcast/evercore29/agen/2333250. Following the webcast, an archived version will be available on the Investors section of the Agenus website at https://investor.agenusbio.com/events-and-presentations.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer and infections. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

ContactAgenus Inc.Nico FrelickInvestor Relations781-674-4616Nico.frelick@agenusbio.com